Item 2.01 Completion of Acquisition or Disposition of Assets



On September 26, 2022, pursuant to the Asset Purchase Agreement (the "Purchase
Agreement"), by and between Emergent BioSolutions Inc. ("Emergent" or the
"Company") and Chimerix, Inc. (the "Seller"), Emergent completed the previously
announced acquisition of the Seller's exclusive worldwide rights to
brincidofovir, including TEMBEXA® and related assets (the "Transaction").
TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and
Drug Administration in June 2021.

At the closing, Emergent paid a cash purchase price of $238 million, exclusive
of customary closing adjustments, using borrowings under its existing revolving
credit facility (the "Purchase Price").

The descriptions of the Transaction herein and under Item 1.01 of the Current
Report on Form 8-K filed by the Company on May 18, 2022 do not purport to be
complete and are qualified in their entirety by reference to the full text of
the Purchase Agreement which was attached as Exhibit 2 to the Form 8-K filed May
18, 2022 and is incorporated herein by reference as Exhibit 2.1. The Purchase
Agreement is intended to provide investors with information regarding its
material terms. It is not intended to provide any other financial information
about the Company or its subsidiaries or affiliates. The representations,
warranties, and covenants contained in the Purchase Agreement were made only for
purposes of that agreement and as of specific dates, are solely for the benefit
of the parties to the Purchase Agreement, may be subject to limitations agreed
upon by the parties, including being qualified by confidential disclosures made
for the purposes of allocating contractual risk between the parties to the
Purchase Agreement instead of establishing these matters as facts, and may be
subject to standards of materiality applicable to the parties that differ from
those applicable to investors. Investors should not rely on the representations,
warranties, or covenants or any description thereof as characterizations of the
actual state of facts or condition of the entities being acquired or any of
their subsidiaries or affiliates. Moreover, information concerning the subject
matter of the representations, warranties, and covenants may have changed after
the date of the Purchase Agreement.

Item 7.01 Regulation FD Disclosure.

On September 26, 2022, Emergent issued a press release announcing the closing of the Transaction, which is furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No.                                              Description
                         Asset Purchase Agreement, dated May 15, 2022, by and between the Company and
2.1*+                    Chimerix, Inc. (incorporated by reference to

Exhibit 2 of the Company's Form


                         8-K filed on May 18, 2022).
99.1                       Press release, dated September 26, 2022.
101                      Emergent BioSolutions Inc. Current Report on Form

8-K, dated September 26,


                         2022 formatted in XBRL (Extensible Business

Reporting Language): Cover Page.


                         The instance document does not appear in the

Interactive Data File because


                         its XBRL tags are embedded within the Inline XBRL

document.


104                      Cover Page Interactive Data File (formatted as

Inline XBRL and contained in


                         Exhibit 101).

* Schedules and exhibits to the Asset Purchase Agreement have been omitted pursuant to Item 601(a)(5)
of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities
and Exchange Commission upon request.
+ Certain portions of this exhibit (indicated by "[***]") have been omitted because the Company has
determined that the information is not material and would likely cause competitive harm to the
Company if publicly disclosed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses